Expert Interview
Discussing Day One Bio’s Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma following Pivotal Phase 2 data results
Ticker(s): DAWN, CMRXInstitution: UCSF
- Full Professor and Neuro-oncologist in the UCSF Department of Neurological Surgery who specializes in the management of brain/spine tumors, neuro-imaging, cognitive and rehabilitative neurology and complementary therapy.
- Director of Translational Research in Neuro-Oncology, the Neuro-Oncology Fellowship Director, and Chair of the UCSF Cancer Center CNS Tumors Site Committee.
- PI on a wide range of clinical trials, including those with convection enhanced delivery (CED), surgical interventions, targeted agents, and immunotherapy with a particular interest and expertise in enriched patient clinical trials, phase 0/I/II trials which administer agents to patients prior to and following surgery, and precision medicine clinical trials.
Please describe your practice as a clinician,how many patients with Low-Grade Glioma do you see on a yearly basis? Can you describe the standard of care, and take us through the most promising upcoming treatments, or interesting clinical trials in this space?
Added By: slingshot_insightsHow much of an unmet need is there in mCRC, specifically, in reducing rates of neutropenia, febrile neutropenia, and diarrhea?
Added By: slingshot_insightsHow efficient are angiogenic blockers such as bevacizumab in combination with conventional chemotherapy for recurrent high-grade glioblastoma?
Added By: slingshot_insightsRecent mutational analysis of 23 initial low-grade gliomas and recurrent tumors from the same patients has challenged the benefits and usage of Temozolomide, when lower-grade brain tumors of patients were removed in patients further treated with Temozolomide, 6 out of 10 times the recurrent tumors were more aggressive and acquired alternative and more mutations. What is your opinion on this?
Regarding Tovorafenib, it recently reported an Overall response rate of 64% and clinical benefit rate of 91% in 69 heavily-pretreated, RANO-evaluable patients. Median duration stood at 8.4 months on therapy as of September 28, 2022, with 77% of patients remaining on treatment.
The most common side effects reported related to tovorafenib were change in hair color (75%), increased creatine phosphokinase (64%), anemia (46%), fatigue (42%) and maculopapular rash (42%).Among a total of 77 treated patients:Participants were heavily pretreated, with a median of three prior lines of systemic therapy (range: 1-9)The median duration of tovorafenib treatment was 8.4 months, with 77% (n=59) of patients on treatment at the time of the data cutoffNearly 60% (n=46) of patients had already received at least one prior MAPK inhibitor prior to study participationCould you please discuss the safety profile of the drug, compared to standard of care?
How likely would you be to prescribe tovorafenib, judging by the clinical trial results to date?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
